Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan-Reference-Cited by-同舟云学术

Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan

Published:2017-06 Issue:6 Volume:33 Page:277-283
ISSN:1607-551X
Container-title:The Kaohsiung Journal of Medical Sciences
language:en
Short-container-title:The Kaohsiung Journal of Medical Sciences

Author:

Chen Tzu-Hua,Chou Mei-Chuan,Lai Chiou-Lian,Wu Shyh-Jong,Hsu Chia-Ling^ORCID,Yang Yuan-Han

Funder

Kaohsiung Medical University

Publisher

Wiley

Subject

General Medicine

Reference38 articles.

1. Rivastigmine in the treatment of Alzheimer's disease: an update;Onor;Clin Interv Aging,2007

2. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease;Corey-Bloom;Int J Geriatr Psychopharmacol,1998

3. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial;Rosler;BMJ,1999

4. Prediction of treatment response to rivastigmine in Alzheimer's dementia;Adler;J Neurol Neurosurg Psychiatry,2004

5. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease;Cutler;Acta Neurol Scand,1998

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review;Frontiers in Neuroscience;2022-09-20

2. Validated LC/MS/MS Method for the Determination of Rivastigmine in Human Plasma: Application to a Pharmacokinetic Study in Egyptian Volunteers to Determine the Effect of Gender and Body Mass Index;Journal of Chromatographic Science;2022-06-25

3. Real-world Evaluation of Tolerability, Safety and Efficacy of Rivastigmine Oral Solution in Patients with Mild to Moderate Alzheimer's Disease Dementia;Clinical Psychopharmacology and Neuroscience;2021-08-31

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil

;Drug Design, Development and Therapy;2020-08

5. Pharmacogenetic considerations when prescribing cholinesterase inhibitors for the treatment of Alzheimer’s disease;Expert Opinion on Drug Metabolism & Toxicology;2020-06-23